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a b s t r a c t
Systemic lupus erythematosus (SLE) can cause numerous skin lesions. Despite being rare, 
lupus-specifi c bullous lesions demonstrate characteristic clinical and immunopathological 
features and require differential diagnosis among numerous bullous conditions that may 
overlap with SLE. The present study presents a case of bullous systemic lupus erythemato-
sus (BSLE) in a pregnant woman.
© 2013 Elsevier Editora Ltda. All rights reserved.
Lúpus eritematoso sistêmico bolhoso em gestante: relato de caso
Palavras-chave:
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Gestantes
r e s u m o
O lúpus eritematoso sistêmico pode apresentar inúmeras lesões cutâneas. As lesões bolho-
sas específi cas do lúpus, apesar de raras, apresentam características clínicas e imunopato-
lógicas próprias e implicam em diagnóstico diferencial entre inúmeras patologias bolhosas 
que podem sobrepor-se ao lúpus eritematoso sistêmico. Apresenta-se um caso de lúpus 
eritematoso sistêmico bolhoso em gestante.
© 2013 Elsevier Editora Ltda. Todos os direitos reservados.
Introduction 
The skin lesions caused by systemic lupus erythematosus 
(SLE), such as malar rash, oral ulcers, discoid lesions and pho-
tosensitivity, are among the most common manifestations 
of the disease. However, bullous eruptions are rare and occur 
in less than 5% of SLE patients.1-4 For this type of collageno-
sis, the vesiculobullous lesions that display distinct clinical 
and immunopathological features are described as bullous 
systemic lupus erythematosus (BSLE) and are part of the dif-
ferential diagnosis for numerous bullous diseases, such as 
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dermatitis herpetiformis, bullous pemphigoid, epidermolysis 
bullosa acquisita and gestational pemphigoid. Here, we pres-
ent the case of a patient with SLE who presented with vesicu-
lobullous lesions during the third trimester of pregnancy.
Case report
The patient was a 25-year-old-woman who had been diag-
nosed with SLE, according to the criteria of the American 
College of Rheumatology (ACR), approximately one year pre-
viously. The patient regularly used chloroquine diphosphate 
250 mg/day, prednisone 5 mg/day and enalapril 40 mg/day. 
Ten months prior, the patient received a routine consultation 
for a confi rmed 12-week pregnancy and presented a malar 
rash. Enalapril was then replaced by methyldopa, chloroquine 
was replaced by hydroxychloroquine, and the prednisone 
dose was increased to 20 mg/day. The patient’s rash subse-
quently improved. 
Four months later, she presented with extensive erythe-
mato-squamous lesions on sun-exposed areas, with mild 
pain and itching. The prednisone dose was increased to 60 
mg (approximately 1 mg/kg), and an early outpatient reas-
sessment with laboratory tests was scheduled. On the fol-
low-up visit, the patient demonstrated bullous, hyperaemic 
and squamous lesions on the face, trunk and upper limbs 
(Fig. 1). She did not report any association between the dis-
ease onset and concomitant infections or use of other drugs. 
There was also no hypertension, abdominal pain or lower 
extremity oedema. 
Blood count analysis showed mild anaemia and lympho-
penia, with normal platelet numbers. No alterations were ob-
served in the peripheral blood analysis. Liver enzymes and 
renal function were normal. Lactate dehydrogenase, uric acid 
and C3 and C4 levels were also normal. The anti-DNA anti-
body titre was 1:80. The extractable nuclear antigen (ENA) 
profi le was negative, and partial urine samples were normal. 
A skin biopsy was performed, and it showed signifi cant ne-
crosis of keratinocytes in the epidermis and a subepidermal 
cleft with a perivascular lymphocytic infl ammatory infi ltrate 
at the dermis/epidermis interface (Fig. 2). The direct immu-
nofl uorescence (DI) results showed granular, dense and con-
tinuous deposits of moderate IgG positivity in the basement 
membrane zone. 
The patient developed fever due to secondary skin infec-
tion. Prednisone 60 mg/day was maintained, and therapy with 
broad-spectrum antibiotics was initiated. Because the foetus 
had a severe intrauterine growth restriction, an emergency 
caesarean was performed. The surgery was uneventful, and 
the child did not demonstrate any complications. 
During hospitalisation, there was slight progression of the 
injuries to the lower limbs and involvement of the oral mu-
cosa. The high dose of corticosteroids was maintained, with 
gradual improvement of the skin condition. After two months, 
the prednisone dose was tapered. The patient has since been 
monitored as an outpatient, and her skin symptoms did not 
return, leaving only hyper- and hypochromic scars on the up-
per limbs and trunk. 
Discussion  
Skin involvement occurs in 70-85% of all patients with SLE. 
Cutaneous manifestations can be classifi ed as specifi c and 
non-specifi c, according to morphological and histological as-
sessment,5 and BSLE is classifi ed as a specifi c acute cutaneous 
manifestation.5,6
In 1973, Pedro and Dahl described the fi rst case of BSLE.4 
This rare form of skin involvement in SLE occurs at an inci-
Fig. 1 – View of the back of the pregnant patient with SLE 
presenting bullous lesions. Fig. 2 – Back skin biopsy showing a subepidermal cleft.
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dence of less than 0.2 cases per million/year.3,7 The clinical 
condition is characterised by vesicles or bullae with serous or 
haemorrhagic content,4,7 in areas both exposed and non-ex-
posed to the sun. Mild to severe itching and mucosal involve-
ment may also be found.4 In addition, the bullae can progress 
without scarring4 or with hypo- or hyperpigmented scarring.7
The histopathology of BSLE is characterised by subepider-
mal bullae with microabscesses of neutrophils in the dermal 
papillae, similar to those found in dermatitis herpetiformis. 
There is also dermal oedema with a perivascular infl ammato-
ry infi ltrate and a predominance of lymphocytes. Some cases 
present with leukocytoclastic vasculitis and extravasation of 
erythrocytes.2,4,6,8,9 In our patient, biopsy revealed necrotic ke-
ratinocytes in the epidermis, lymphocytic infi ltration at the 
dermis/epidermis interface and in the subepidermal cleft and 
a perivascular infl ammatory infi ltrate in the dermis. These 
fi ndings can also be found in erythema multiforme and in 
Rowell’s Syndrome, the latter being described as an associa-
tion of lupus and erythema multiforme in patients with an-
ti-Ro/SS-A antibodies and rheumatoid factor.1,10 Because the 
DI results for our patient showed a moderate degree of IgG 
deposition in the basement membrane zone, which is char-
acteristic of BSLE, and because the antibodies often present 
in Rowell Syndrome were not detected, the diagnosis of BSLE 
was the most suitable.
The diagnostic criteria for BSLE proposed by Camisa and 
Sharma include a diagnosis of SLE based on the following cri-
teria of the ACR: vesicles and bullae mainly located on sun-
exposed areas; histopathological fi ndings similar to those 
found in dermatitis herpetiformis; and deposition of IgG, IgM 
or both and often IgA in the basement membrane zone.4,8,9 
Gammon and Buggaman classifi ed BSLE into two different 
subtypes: type 1, in which patients have circulating anti-col-
lagen VII antibodies, and type 2, in which no specifi c antibod-
ies are present.8,9
The pathology of BSLE is thought to be associated with an-
tibodies against the non-collagenous domain of collagen VII, 
as well as other antibodies against different components of 
the basement membrane. In particular, these immunoglobu-
lins are thought to block the connection between the base-
ment membrane and the dermal papillae by complement 
activation and recruitment and activation of neutrophils, re-
sulting in the formation of a subepidermal bulla.3,8,9,11
It remains unclear whether there is a relationship between 
bullous eruptions and symptom fl ares in SLE. Vesiculobullous 
lesions can develop without clinical or laboratory evidence of 
disease worsening; however, in some cases, there is a clear as-
sociation between skin manifestations and renal activity.2-4,7,9 
The patient described herein demonstrated no other signs of 
SLE activity in other organs.
The behaviour of SLE during pregnancy has been dis-
cussed,12,13 and most patients are believed to exhibit exacer-
bation of skin lesions during pregnancy, with a 60% chance of 
prematurity and 2- to 4-fold increased likelihood of miscar-
riage when the disease is active. One important differential 
diagnosis in the context of bullous diseases in pregnancy is 
gestational pemphigoid, also known as herpes gestationis. 
This clinical presentation is very similar to BSLE, including 
histopathology results showing subepidermal bulla, which, 
in this case, contained numerous eosinophils. The DI results 
generally also show linear deposition of C3 in the basement 
membrane. In general, however, pregnancy does not seem to 
be a risk factor for the appearance of bullous lesions, given 
that we did not fi nd other case reports of BSLE in pregnant 
women.
Dapsone is the drug of choice for BSLE treatment.2,3,9,11 Pa-
tients generally respond dramatically to this drug, as the for-
mation of new bullae is interrupted within 1-2 days of treat-
ment and the existing lesions are healed in a few days, even 
with low doses of 25-50 mg/day.3,9 Dapsone has been assigned 
to pregnancy category C. Other drugs such as prednisone, aza-
thioprine, cyclophosphamide, mycophenolate mofetil and an-
timalarial drugs may also be effective for BSLE treatment.3 For 
example, Malcangi et al. described the case of a BSLE patient 
who demonstrated a good response to the use of methotrex-
ate.14 However, because our patient was pregnant and using 
hydroxychloroquine, we opted for treatment with high-dose 
corticosteroids and obtained a satisfactory response.
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